المؤلفون: Sun, Shuyang, Ding, Ziqiang, Gao, Li, Hammock, Bruce D, Huang, Xianing, Xu, Zhi Ping, Wang, Xuan, Cheng, Qihong, Mo, Fengzhen, Shi, Wei, Xie, Shenxia, Liu, Aiqun, Li, Haixia, Yang, Xiaomei, Lu, Xiaoling

المصدر: Theranostics. 13(14)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Orphan Drug, Immunization, Vaccine Related, Immunotherapy, Rare Diseases, Gene Therapy, Genetics, Biotechnology, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Humans, Animals, Mice, Receptors, Chimeric Antigen, Cell Line, Tumor, T-Lymphocytes, Immunotherapy, Adoptive, Cell Proliferation, Xenograft Model Antitumor Assays, nanobody, CAR-T cells, DC/tumor fusion vaccines, EGFRvIII, solid tumor, Oncology and carcinogenesis

الوصف: Background: Chimeric antigen receptor (CAR) T-cell therapy is practical in treating cancers of hematopoietic origin, but of that in solid tumors compromises efficacy for the loss of the antigen recognized by the CAR. However, dendritic cell (DC)/tumor fusion vaccines present a spectrum of known or unknown tumor antigens to stimulate T cell expansion and enhanced T cell response. Developing a new strategy of enhanced nanobody-based CAR-T (Nb-CAR-T) cells antitumor activity by DC/tumor fusion vaccines stimulation would provide guidance for more effective CAR-T cell therapies. Methods: Considering the therapeutic potential of nanobody (Nb), we first screened EGFRvIII Nb, then constructed and verified the function of EGFRvIII Nb-CAR-T cells in vitro and in vivo. We further combined DC/tumor fusion vaccines to boost EGFRvIII Nb-CAR-T cells antitumor effect, which was evaluated in vitro Nb-CAR-T cell function and in the tumor-bearing xenograft mouse models. Results: We had for the first time successfully selected EGFRvIII Nb for the generation of the novel EGFRvIII Nb-CAR-T cells. Importantly, our results suggested that DC/tumor fusion vaccines stimulate Nb-CAR-T cells response not only in improving T cell proliferation, T cell activation, cytokine secretion and tumor-specific cytotoxicity in vitro, but also significantly reducing tumor burden, prolonging survival and improving Nb-CAR-T cells infiltration. Conclusions: We have innovatively shown that DC/tumor fusion vaccines significantly enhance the efficacy of Nb-CAR-T cells against solid tumors. This new strategy has provided a promising therapeutic platform for promoting the clinical treatment of CAR-T cells therapy.

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/18m6w3hn
https://escholarship.org/content/qt18m6w3hn/qt18m6w3hn.pdf

المؤلفون: Mishima, Saori, Naito, Yoichi, Akagi, Kiwamu, Hayashi, Naomi, Hirasawa, Akira, Hishiki, Tomoro, Igarashi, Ataru, Ikeda, Masafumi, Kadowaki, Shigenori, Kajiyama, Hiroaki, Kato, Motohiro, Kenmotsu, Hirotsugu, Kodera, Yasuhiro, Komine, Keigo, Koyama, Takafumi, Maeda, Osamu, Miyachi, Mitsuru, Nishihara, Hiroshi, Nishiyama, Hiroyuki, Ohga, Shouichi, Okamoto, Wataru, Oki, Eiji, Ono, Shigeru, Sanada, Masashi, Sekine, Ikuo, Takano, Tadao, Tao, Kayoko, Terashima, Keita, Tsuchihara, Katsuya, Yatabe, Yasushi, Yoshino, Takayuki, Baba, Eishi^{Aff17, IDs10147023023979_cor32}

المصدر: International Journal of Clinical Oncology. 28(10):1237-1258

المؤلفون: Zhang, Miaomiao, Wang, Yuanyuan, Chen, Xinzu, Zhang, Fan, Chen, Jiannan, Zhu, Hongqiao, Li, Jun, Chen, Zhengliang, Wang, Aying, Xiao, Yao, Chen, Zilu, Dong, Yunfei, Yin, Xuechen, Ji, Feng, Liu, Jie, Liang, Junqing, Pan, Feiyan, Guo, Zhigang, He, Lingfeng^{Aff1, IDs12094023031611_cor19}

المصدر: Clinical and Translational Oncology. 25(10):2972-2982

المؤلفون: Chakraborty, Abhijit, Dutta, Preyangsee, Saha, Dwaipayan, Singh, Mayank, Prasad, Chandra Prakash, Pushpam, Deepam, Shankar, Abhishek^{Aff5, IDs4315202300046x_cor7}, Saini, Deepak

المصدر: Current Tissue Microenvironment Reports. 4(3):29-40

المؤلفون: Akash, Mohammad Mehedi Hasan, Chakraborty, Nilotpal, Mohammad, Jiyan^{Aff3, Aff4}, Reindl, Katie, Basu, Saikat^{Aff1, IDs427570220150x_cor5}

المصدر: Experimental and Computational Multiphase Flow. 5(3):319-329

المؤلفون: Ma, Yarui, Gan, Jingbo, Bai, Yinlei, Cao, Dandan, Jiao, Yuchen^{Aff1, IDs1168402310186_cor5}

المصدر: Frontiers of Medicine. 17(4):649-674

المؤلفون: Mishima, Saori, Naito, Yoichi, Akagi, Kiwamu, Hayashi, Naomi, Hirasawa, Akira, Hishiki, Tomoro, Igarashi, Ataru, Ikeda, Masafumi, Kadowaki, Shigenori, Kajiyama, Hiroaki, Kato, Motohiro, Kenmotsu, Hirotsugu, Kodera, Yasuhiro, Komine, Keigo, Koyama, Takafumi, Maeda, Osamu, Miyachi, Mitsuru, Nishihara, Hiroshi, Nishiyama, Hiroyuki, Ohga, Shouichi, Okamoto, Wataru, Oki, Eiji, Ono, Shigeru, Sanada, Masashi, Sekine, Ikuo, Takano, Tadao, Tao, Kayoko, Terashima, Keita, Tsuchihara, Katsuya, Yatabe, Yasushi, Yoshino, Takayuki, Baba, Eishi^{Aff17, IDs10147023023608_cor32}

المصدر: International Journal of Clinical Oncology. 28(8):941-955

المؤلفون: Qing Wei, Peijing Li, Teng Yang, Jiayu Zhu, Lu Sun, Ziwen Zhang, Lu Wang, Xuefei Tian, Jiahui Chen, Can Hu, Junli Xue, Letao Ma, Takaya Shimura, Jianmin Fang, Jieer Ying, Peng Guo, Xiangdong Cheng

المصدر: Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-32 (2024)

مصطلحات موضوعية: Antibody-drug conjugate, Solid tumor, Combination therapy, Immunotherapy, Targeted therapy, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1756-8722

URL الوصول: https://doaj.org/article/66d0042687784ac5a8494718d389400a

المؤلفون: Bei Zhou, Yan Yang, Yan Kang, Jingjing Hou, Yun Yang

المصدر: Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-11 (2024)

مصطلحات موضوعية: Macrophage, Solid tumor, Immunotherapy, Immune factors, Medicine, Cytology, QH573-671

الوصف: Abstract Tumor immunotherapy, which targets immune checkpoints, presents a promising strategy for the treatment of various cancer types. However, current clinical data indicate challenges in its application to solid tumors. Recent studies have revealed a significant correlation between the degree of immune response in immunotherapy and the tumor microenvironment, particularly with regard to tumor-infiltrating immune cells. Among these immune cells, macrophages, a critical component, are playing an increasingly vital role in tumor immunotherapy. This review focuses on elucidating the role of macrophages within solid tumors and provides an overview of the progress in immunotherapy approaches centered around modulating macrophage responses through various immune factors. Video Abstract

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1478-811X

URL الوصول: https://doaj.org/article/b4b7e04d7d3c4c928cfbde4bac66a6ff

المؤلفون: Chunwei Xu, Qian Wang, Dong Wang, Wenxian Wang, Wenfeng Fang, Ziming Li, Aijun Liu, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Long Huang, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Fei Pang, Qingqing He, Jintao Huang, Kai Wang, Fan Wu, Bingwei Xu, Liping Wang, Youcai Zhu, Li Lin, Yanru Xie, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Jia Wei, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yue Feng, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Zhaofeng Wang, Yue Hao, Zhen Wang, Bin Wan, Donglai Lv, Shengjie Yang, Jin Kang, Jiatao Zhang, Chao Zhang, Juanjuan Ou, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Zhefeng Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Yiping Zhang, Xixu Zhu, Yi Shen, Shenglin Ma, Biyun Wang, Lu Si, Yong Song, Yuanzhi Lu, Jing Chen, Zhengbo Song

المصدر: Global Medical Genetics, Vol 11, Iss 01, Pp 086-099 (2024)

مصطلحات موضوعية: tyrosine receptor kinase, monoclonal antibodies, precision medicine, targeted therapy, solid tumor, fusion, Genetics, QH426-470, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: The fusion genes NRG1 and NRG2, members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, NRG1 retains its EGF-like active domain, binds to the ERBB ligand family, and triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. CD74 and SLC3A2 are the most frequently observed fusion partners. RNA-based next-generation sequencing is the primary method for detecting NRG1 and NRG2 gene fusions, whereas pERBB3 immunohistochemistry can serve as a rapid prescreening tool for identifying NRG1-positive patients. Currently, there are no approved targeted drugs for NRG1 and NRG2. Common treatment approaches involve pan-ERBB inhibitors, small molecule inhibitors targeting ERBB2 or ERBB3, and monoclonal antibodies. Given the current landscape of NRG1 and NRG2 in solid tumors, a consensus among diagnostic and treatment experts is proposed, and clinical trials hold promise for benefiting more patients with NRG1 and NRG2 gene fusion solid tumors.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2699-9404

URL الوصول: https://doaj.org/article/9709bead602f46d78dbb13fcba8fc177